700 Main Street
About Navitor PharmaceuticalsAbout Navitor Pharmaceuticals
A powerful therapeutic approach targeting the central regulator of nutrient signaling, cellular metabolism and growth
New scientific insights are emerging regarding the primal signaling pathways that direct an organism’s metabolic response to conditions in its environment—such as dynamic changes in the availability of nutrients, energy, oxygen and other factors—and the role of these metabolic signaling pathways in disease. Navitor’s drug discovery platform leverages proprietary intellectual property and know-how related to key targets within nutrient signaling pathways and their fundamental role in disease processes. Our proprietary approach targeting nutrient signaling offers an entirely new treatment approach for a broad range of chronic and rare diseases.
Selective regulation of mTORC1 offers a new and targeted approach to expand the therapeutic potential of a clinically validated pathway
The company’s proprietary drug discovery platform is built on new insights into the mTORC1-mediated nutrient signaling pathway. mTORC1 is at the center of the signaling network that integrates the cell’s response to nutrient availability thereby regulating cellular growth and function. Navitor was founded based on groundbreaking discoveries related to the mTORC1 pathway and nutrient signaling mechanisms by its scientific founder Dr. David Sabatini at the Whitehead Institute for Biomedical Research. Dr. Sabatini’s work has been instrumental in the discovery of the mTOR kinase and the two multi-protein complexes, mTORC1 and mTORC2, each of which mediates distinct aspects of the signaling network that regulates the activity of the mTOR kinase and the cell’s response to the environment.
Navitor’s proprietary drug discovery platform is designed to develop first-in-class selective modulators of mTORC1. While several approved drugs target the broad mTOR pathway for specific disease applications, the use of current mTOR-targeted drugs has been limited since they inhibit both mTORC1 and mTORC2, leading to undesirable side-effects when used chronically. The design of selective drugs targeting mTORC1, which is the focus of Navitor’s drug discovery and development efforts, is highly desirable since it is the key mTOR complex that regulates protein synthesis, cellular metabolism and growth in response to nutrient availability. As a critical regulatory pathway, mTORC1 is often dysregulated in multiple diseases across several important therapeutic areas.
Proprietary platform targeting mTORC1 to develop novel product candidates for a range of diseases
Navitor’s technology is applicable to a wide range of diseases in which nutrient signaling via the mTORC1 pathway is dysregulated. Navitor’s approach is to selectively “turn up” or “turn down” these nutrient-responsive cellular pathways in order to restore normal mTORC1 function.
When the mTORC1 pathway becomes hyperactive in its signaling response to excess nutrients, it is responsible for diseases such as obesity, type 2 diabetes, neurodegenerative diseases, and autoimmune and chronic inflammatory diseases, as well as rare metabolic and mitochondrial diseases. Conversely, the reduced response of the mTORC1 pathway is commonly associated with deficits in skeletal muscle growth observed in musculoskeletal diseases such as age-related sarcopenia, cachexia due to disease, and muscle atrophy due to immobilization or orthopedic surgery.
By selectively targeting aberrant cellular nutrient signaling mediated by the mTORC1 pathway, Navitor is creating a new class of therapeutics designed to rebalance these signals to restore normal function and address the underlying biology of multiple diseases.
World-class team and proprietary technology positioned for successful drug development
Navitor is led by an experienced management and scientific team with a proven track record for discovering groundbreaking drugs and building successful drug development companies. The company’s founding intellectual property is based on the scientific work of Dr. David Sabatini at the Whitehead Institute. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
24 articles with Navitor Pharmaceuticals
Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138
Supernus Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, and Navitor Pharmaceuticals, Inc., a privately-held company leading the discovery and development of mTORC1-targeted therapeutics, announced a joint development and option agreement for Navitor’s mTORC1 activator, NV-5138.
Navitor’s Three Phase 1 Studies for NV-5138 Show Antidepressant Effects and Biomarker Impact, Supporting Further Development of Direct Activator of mTORC1 in Depression
Navitor Pharmaceuticals, Inc., the leader in the discovery and development of mTORC1-targeted therapeutics designed to help patients live longer and healthier lives, announced today the successful completion of three Phase 1 studies for NV-5138, which is in development for patients with depression.
7/19/2019Pharma and biotech companies from across the globe expand their leadership teams and boards.
Navitor Expands Leadership Team with Appointment of James Randall Owen, M.D. as Chief Medical Officer
Navitor Pharmaceuticals, Inc., the leader in the discovery and development of mTORC1-targeted therapeutics designed to help patients live longer and healthier lives, today announced the appointment of James Randall “Randy” Owen, M.D. as the Company’s first Chief Medical Officer.
Navitor Pharmaceuticals Announces Peer-Reviewed Publication in Journal of Clinical Investigation Highlighting Rapid Antidepressant Effects of NV-5138
Navitor Pharmaceuticals, Inc., the leader in the development of mTORC1-targeted therapeutics designed to help patients live longer and healthier lives, announced today the publication of a peer-reviewed article in the Journal of Clinical Investigation, highlighting the rapid and long-lasting antidepressant effects of NV-5138 in behavioral models of depression and treatment response.
Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, a Novel mTORC1 Activator in Patients with Treatment-Resistant Depression
Navitor Pharmaceuticals, the leader in the development of mTORC1-targeted therapeutics designed to help patients live longer and healthier lives, announced today the initiation of Part B of its Phase 1 clinical study with its lead candidate, NV-5138, for treatment-resistant depression (TRD).
Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing innovative therapeutics targeting the activity of mTORC1, or Complex 1 of the mechanistic target of rapamycin, for neurological disorders and chronic diseases of aging, today announced that Thomas E. Hughes, Ph.D., Chief Executive Officer, will present a corporate overview at the 30th Annual Piper Jaffray Healthcare Conference.
The Baltimore Longitudinal Study of Aging was launched in 1958 by the National Institutes of Health. The idea was to follow and study the lives of healthy, active people over their lifetimes, rather than after they were dead.
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
Biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those adjustments.
8/3/2018Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer.
Aug. 2, 2018 20:30 UTC Navitor Pharmaceuticals Appoints Thomas E. Hughes, Ph.D. as Chief Executive Officer Former CEO and President of Zafgen brings pharmaceutical development and public biotechnology company leadership experience as Navitor builds product pipeline George P. Vlasuk, Ph.D. to remain as President and appointed Chief Scientific Officer CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Navito
Navitor Pharmaceuticals Initiates a Clinical Study of NV-5138, a Novel, Oral Small Molecule for Treatment-Resistant Depression
NV-5138 is a specific and direct activator of mTORC1, a cellular pathway required for the efficacy of many rapid acting antidepressants
Navitor Pharmaceuticals to Present at UBS Global Healthcare Conference
Navitor Pharmaceuticals to Develop NV-5138, a Specific Activator of mTORC1 for Treatment-Resistant Depression, Based on Promising Data Presented at Society for Neuroscience 2017
First data on NV-5138 demonstrating direct mTORC1 activation resulting in ketamine-like rapid antidepressant effects in preclinical animal models.
Navitor Pharmaceuticals’ Scientific Founder Makes Seminal Discoveries Related to Role of Nutrient Sensors in mTOR Regulation and Activity
Today, Dr. Sabatini published in the journal Science the discovery of a new nutrient sensor in the mTORC1 pathway, SAMTOR
Navitor Pharmaceuticals’ Scientific Founder Makes Landmark Discovery Of The Molecular Sensor For The Amino Acid Leucine
Navitor Pharmaceuticals Appoints David M. Madden To Board Of Directors And Michael N. Hall, Phd, To Scientific Advisory Board